Relay Therapeutics' SWOT analysis: AI-driven drug discovery stock faces pivotal phase

Relay Therapeutics (RLAY) is advancing RLY-2608, a PI3Ka inhibitor for breast cancer, towards a Phase 3 trial (ReDiscover-2) slated for mid-2025, following promising Phase 2 data showing improved progression-free survival, particularly in kinase domain mutation patients (18.4 months). The company has implemented cost-cutting to extend its cash runway through 2029, but faces increasing competition in the PI3Ka inhibitor space after the acquisition of Scorpion Therapeutics; analysts have mixed price targets with an overall buy rating, while InvestingPro data suggests the stock may be undervalued despite negative EBITDA.

Analysis

Relay Therapeutics (RLAY) is at a critical juncture with its lead PI3Ka inhibitor, RLY-2608, for PIK3CA-mutated breast cancer, as it prepares for a pivotal Phase 3 trial (ReDiscover-2) scheduled to commence in mid-2025. Promising Phase 2 ReDiscover trial data demonstrated an improved median progression-free survival (PFS) to 10.3 months overall, and notably 18.4 months for patients with kinase domain mutations, alongside a 39% overall response rate and a manageable safety profile, with hyperglycemia being mostly mild (3.1% Grade 3 or higher). Financially, RLAY has implemented cost-cutting measures, including workforce reductions, extending its cash runway through 2029, past the anticipated Phase 3 data readout, and maintains a strong balance sheet with more cash than debt and a current ratio of 19.96x. However, the company is experiencing significant cash burn, evidenced by a negative EBITDA of $373 million in the last twelve months and a projected negative EPS of -$1.80 for fiscal year 2025. Despite an average "Buy" consensus from analysts, price targets ranging from $4 to $29, and InvestingPro analysis suggesting undervaluation with the stock trading at 0.77x book value, RLAY shares have declined 56% over the past year and face increased competition in the PI3Ka inhibitor space, underscored by the recent acquisition of Scorpion Therapeutics. The success of the FDA-aligned Phase 3 trial, which will evaluate RLY-2608 in both kinase mutation subgroups and the broader intention-to-treat (ITT) population, is paramount and presents substantial upside potential if results are positive, but also considerable downside risk given the company's narrowed focus on this single asset and the execution risks inherent in late-stage clinical development.

Key Decisions for Investors

• Investors should closely monitor the initiation and subsequent data readouts from the ReDiscover-2 Phase 3 trial for RLY-2608, as its outcome represents the primary determinant of Relay Therapeutics' future valuation.
• Careful consideration should be given to the company's financial health, particularly its cash burn rate relative to its extended cash runway through 2029, and the potential need for future financing.
• The current stock valuation, appearing undervalued by some metrics, should be weighed against significant risks including heightened competition in the PI3Ka inhibitor market, the binary nature of Phase 3 trial outcomes, and existing stock price volatility.
• Upcoming ASCO updates throughout 2025 will serve as crucial near-term catalysts, providing further insights into RLY-2608's evolving efficacy and safety profile, which could significantly influence investment sentiment.